paladin - The only thing that got a little scrambled in you message is the Crestor/Lipitor replacement for SGLT2's and DPP4's. Everything else looks pretty close. As Bear says the placebo experience was better than they planned for. Although there seems to be some hair on this there is lots to work with to continue moving this story forward. Heck we could wake up tomorrow to a hault and great news or not so great news, who knows. Someone on this board pointed out that most or many of the positive responses we saw in BETonMACE were in the low functioning kidney group, the presentation on March 26th may make the world pay attention...or not. IMO there is something to a drug that can reduce CHF by over 50% in a certain segment of the trial population no matter how small that population was. Getting people to look at a new science has and will always be a challenge. Being a small, Canadaian Biotech increases those challenges. Finding that point where the story is no longer to good to be true is where they are at at this time. Lets just hope the recent actions in the overall markets don't tromp on what otherwise might be some exceptional news.

tada